$151.31
0.94% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Biogen Stock price

$151.31
-8.52 5.33% 1M
-77.41 33.84% 6M
-107.46 41.53% YTD
-110.62 42.23% 1Y
-82.88 35.39% 3Y
-148.78 49.58% 5Y
-165.02 52.17% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+1.41 0.94%
ISIN
US09062X1037
Symbol
BIIB
Sector
Industry

Key metrics

Market capitalization $22.05b
Enterprise Value $27.00b
P/E (TTM) P/E ratio 13.67
EV/FCF (TTM) EV/FCF 13.86
EV/Sales (TTM) EV/Sales 2.93
P/S ratio (TTM) P/S ratio 2.39
P/B ratio (TTM) P/B ratio 1.35
Revenue growth (TTM) Revenue growth -3.98%
Revenue (TTM) Revenue $9.23b
EBIT (operating result TTM) EBIT $2.12b
Free Cash Flow (TTM) Free Cash Flow $1.95b
Cash position $1.70b
EPS (TTM) EPS $11.07
P/E forward 11.99
P/S forward 2.29
EV/Sales forward 2.80
Short interest 2.11%
Show more

Create a Free Account to create an Biogen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Biogen Stock Analysis

Analyst Opinions

36 Analysts have issued a Biogen forecast:

21x Buy
58%
15x Hold
42%

Analyst Opinions

36 Analysts have issued a Biogen forecast:

Buy
58%
Hold
42%

Financial data from Biogen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
9,229 9,229
4% 4%
100%
- Direct Costs 2,975 2,975
3% 3%
32%
6,254 6,254
4% 4%
68%
- Selling and Administrative Expenses 1,703 1,703
14% 14%
18%
- Research and Development Expense 1,803 1,803
19% 19%
20%
2,748 2,748
19% 19%
30%
- Depreciation and Amortization 629 629
6% 6%
7%
EBIT (Operating Income) EBIT 2,119 2,119
23% 23%
23%
Net Profit 1,615 1,615
10% 10%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Biogen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biogen Stock News

Positive
Market Watch
one day ago
Also: Technical analysis for trading in shares of Nvidia, how MicroStrategy burns cash, and tips for people with student loans in 2025
Positive
Reuters
16 days ago
The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen's amyotrophic lateral sclerosis drug Qalsody after finding instances of coverage denial.
Neutral
Investors Business Daily
18 days ago
Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025.
More Biogen News

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Head office United States
CEO Christopher Viehbacher
Employees 7,570
Founded 1978
Website www.biogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today